연구용제품시약 > Antibody
InVivoSIM anti-human CTLA-4 (Ipilimumab Biosimilar)
바이오엑스셀코리아
BioXCell 은(www.bxcell.com) (www.bxcell.co.kr)
In Vivo용 Antibody를 1mg,5mg,25mg,50mg,100mg
용량으로 직접 제조하며, 합리적인 가격으로
공급하는 회사입니다.
▶약 300여종의 제품을 보유(Mouse, Human, Rat ..)
▶high quality
▶bulk quantity (milligram to gram)
▶low endotoxin levels
▶well suited for in-vivo preclinical studies.
BioXCell Biosimilars "InVivoSIM™"
InVivoSIM anti-human CTLA-4
(Ipilimumab Biosimilar)
Catalog # SIM0004
SIZE: 1mg,5mg,25mg,50mg,100mg
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Ipilimumab making it ideal for research use. This Ipilimumab biosimilar reacts with human CTLA-4 (cytotoxic T lymphocyte antigen-4) also known as CD152.
CTLA-4 is a 33 kDa cell surface receptor encoded by the Ctla4 gene that belongs to the CD28 family of the Ig superfamily.
CTLA-4 is expressed on activated T and B lymphocytes. CTLA-4 is structurally similar to the T-cell co-stimulatory protein, CD28, and both molecules bind to the B7 family members B7-1 (CD80) and B7-2 (CD86). Upon ligand binding, CTLA-4 negatively regulates cell-mediated immune responses.
CTLA-4 plays roles in induction and/or maintenance of immunological tolerance, thymocyte development, and regulation of protective immunity.
CTLA-4 is among a group of inhibitory receptors being used as cancer treatment targets through immune checkpoint blockade. Ipilimumab binds to CTLA-4, blocking the inhibitory signal, which allows the cytotoxic T cells to kill cancer cells.
Isotype | human IgG1 |
Recommended Isotype Control(s) | InVivoPlus™ human IgG1 isotype control |
Recommended Dilution Buffer | InVivoPure™ pH 7.0 Dilution Buffer |
Immunogen | Human CTLA-4 |
Reported Applications |
|
Formulation |
|
Endotoxin |
|
Aggregation |
|
Sterility | 0.2 μM filtered |
Production | Purified from cell culture supernatant |
Purification | Protein A |
Molecular Weight | 150 kDa |
Murine Pathogen Test Results |
|
Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
Catalog No. |
Product Name |
Reactivity |
Antigen |
Host |
Isotype |
Reported Applications |
SIM0001 |
InVivoSIM anti-human TNFα |
human |
TNFα |
Human |
IgG1 |
TNFα neutralization; FC ELISA; IF; IP; IHC; WB |
SIM0002 |
InVivoSIM anti-human EGFR |
human |
EGFR |
Human |
IgG1 |
EGFR blockade; ELISA; FC |
SIM0003 |
InVivoSIM anti-human PD-1 |
human |
PD-1 |
Human |
IgG4 |
Blocking of PD-1/PD-L signaling FC; IHC; WB |
SIM0004 |
InVivoSIM anti-human CTLA-4 |
human |
CTLA-4 |
Human |
IgG1 |
CTLA-4 neutralization; FC; ELISA; WB |
SIM0005 |
InVivoSIM anti-human HER2 |
human |
HER2 |
Human |
IgG1 |
FC; ELISA; IHC; WB |
SIM0006 |
InVivoSIM anti-human TNFα |
human |
TNFα |
Human |
IgG1 |
TNFα neutralization; FC; ELISA; WB |
SIM0007 |
InVivoSIM anti-human VEGF |
human |
VEGF |
Human |
IgG1 |
VEGF neutralization; FC; ELISA;IP |
SIM0008 |
InVivoSIM anti-human CD20 |
human |
CD20 |
Human |
IgG1 |
FC; ELISA; WB |
SIM0009 |
InVivoSIM anti-human PD-L1 |
human |
PD-L1 |
Human |
IgG1 |
FC; WB |
SIM0010 |
InVivoSIM anti-human PD-1 (Pembrolimumab Biosimilar) |
human |
PD-1 |
Human |
IgG4 |
Blocking of PD-1/PD-L signaling Functional assays |
SIM0011 |
InVivoSIM anti-human C5 (Eculizumab Biosimilar) |
human |
C5 |
Human |
IgG4 |
Inhibition of the activation of C5 Functional assays; ELISA; IP |
SIM0012 |
InVivoSIM anti-human VEGFR-2 (Ramucirumab Biosimilar) |
human |
VEGFR-2 |
Human |
IgG1 |
Functional assays; IHC; FC |
SIM0013 |
InVivoSIM anti-human IL-17A (Secukinumab Biosimilar) |
human |
IL-17A |
Human |
IgG1 |
Functional assays; ELISA; IF; IHC; FC |
SIM0014 |
InVivoSIM anti-human IL-6R (Tocilizumab Biosimilar) |
human |
IL-6R |
Human |
IgG1 |
Functional assays; ELISA |
자세한 문의사항은 본사로 문의해 주시기 바랍니다.
(BioXCell Korea는 BioClone의 자회사 입니다)
바이오엑스셀 코리아 (www.bxcell.co.kr)
Tel : 02)2013-8240 Fax : 02)2013-8243
본 정보는 "바이오엑스셀코리아" (으)로 문의 바랍니다.